N Ari Wijetunga1, Thomas J Belbin2, Robert D Burk3, Kathleen Whitney2, Maria Abadi2, John M Greally4, Mark H Einstein5, Nicolas F Schlecht6. 1. Department of Genetics and Center for Epigenomics, Albert Einstein College of Medicine, Bronx, NY 10461, USA. 2. Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. 3. Department of Pediatrics (Genetics), Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA. 4. Department of Genetics and Center for Epigenomics, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Pediatrics (Genetics), Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: john.greally@einstein.yu.edu. 5. Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: mark.einstein@einstein.yu.edu. 6. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: nicolas.schlecht@einstein.yu.edu.
Abstract
OBJECTIVE: To conduct a comprehensive mapping of the genomic DNA methylation in CDKN2A, which codes for the p16(INK4A) and p14(ARF) proteins, and 14 of the most promising DNA methylation marker candidates previously reported to be associated with progression of low-grade cervical intraepithelial neoplasia (CIN1) to cervical cancer. METHODS: We analyzed DNA methylation in 68 HIV-seropositive and negative women with incident CIN1, CIN2, CIN3 and invasive cervical cancer, assaying 120 CpG dinucleotide sites spanning APC, CDH1, CDH13, CDKN2A, CDKN2B, DAPK1, FHIT, GSTP1, HIC1, MGMT, MLH1, RARB, RASSF1, TERT and TIMP3 using the Illumina Infinium array. Validation was performed using high resolution mapping of the target genes with HELP-tagging for 286 CpGs, followed by fine mapping of candidate genes with targeted bisulfite sequencing. We assessed for statistical differences in DNA methylation levels for each CpG loci assayed using univariate and multivariate methods correcting for multiple comparisons. RESULTS: In our discovery sample set, we identified dose dependent differences in DNA methylation with grade of disease in CDKN2A, APC, MGMT, MLH1 and HIC1, whereas single CpG locus differences between CIN2/3 and cancer groups were seen for CDH13, DAPK1 and TERT. Only those CpGs in the gene body of CDKN2A showed a monotonic increase in methylation between persistent CIN1, CIN2, CIN3 and cancers. CONCLUSION: Our data suggests a novel link between early cervical disease progression and DNA methylation in a region downstream of the CDKN2A transcription start site that may lead to increased p16(INK4A)/p14(ARF) expression prior to development of malignant disease.
OBJECTIVE: To conduct a comprehensive mapping of the genomic DNA methylation in CDKN2A, which codes for the p16(INK4A) and p14(ARF) proteins, and 14 of the most promising DNA methylation marker candidates previously reported to be associated with progression of low-grade cervical intraepithelial neoplasia (CIN1) to cervical cancer. METHODS: We analyzed DNA methylation in 68 HIV-seropositive and negative women with incident CIN1, CIN2, CIN3 and invasive cervical cancer, assaying 120 CpG dinucleotide sites spanning APC, CDH1, CDH13, CDKN2A, CDKN2B, DAPK1, FHIT, GSTP1, HIC1, MGMT, MLH1, RARB, RASSF1, TERT and TIMP3 using the Illumina Infinium array. Validation was performed using high resolution mapping of the target genes with HELP-tagging for 286 CpGs, followed by fine mapping of candidate genes with targeted bisulfite sequencing. We assessed for statistical differences in DNA methylation levels for each CpG loci assayed using univariate and multivariate methods correcting for multiple comparisons. RESULTS: In our discovery sample set, we identified dose dependent differences in DNA methylation with grade of disease in CDKN2A, APC, MGMT, MLH1 and HIC1, whereas single CpG locus differences between CIN2/3 and cancer groups were seen for CDH13, DAPK1 and TERT. Only those CpGs in the gene body of CDKN2A showed a monotonic increase in methylation between persistent CIN1, CIN2, CIN3 and cancers. CONCLUSION: Our data suggests a novel link between early cervical disease progression and DNA methylation in a region downstream of the CDKN2A transcription start site that may lead to increased p16(INK4A)/p14(ARF) expression prior to development of malignant disease.
Authors: Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk Journal: J Med Virol Date: 2002-11 Impact factor: 2.327
Authors: Ana Paula Sarreta Terra; Eddie Fernando Candido Murta; Paulo José Maluf; Otávia Luísa Silva Damas Caballero; Mariana Brait; Sheila Jorge Adad Journal: Tumori Date: 2007 Nov-Dec
Authors: Lucas Delmonico; Mauricio Augusto Silva Magalhães Costa; Romario José Gomes; Pâmella De Oliveira Vieira; Ana Beatriz Passos Da Silva; Marcia V Fournier; Luciano Rios Scherrer; Carolina Maria De Azevedo; Maria Helena Faria Ornellas; Gilda Alves Journal: Oncol Lett Date: 2020-02-10 Impact factor: 3.111
Authors: Steven F Gameiro; Bart Kolendowski; Ali Zhang; John W Barrett; Anthony C Nichols; Joe Torchia; Joe S Mymryk Journal: Oncotarget Date: 2017-08-03